ATE359367T1 - Ldl-rezeptor - Google Patents

Ldl-rezeptor

Info

Publication number
ATE359367T1
ATE359367T1 AT98917374T AT98917374T ATE359367T1 AT E359367 T1 ATE359367 T1 AT E359367T1 AT 98917374 T AT98917374 T AT 98917374T AT 98917374 T AT98917374 T AT 98917374T AT E359367 T1 ATE359367 T1 AT E359367T1
Authority
AT
Austria
Prior art keywords
gene
diseases
methods
diabetes
nucleic acid
Prior art date
Application number
AT98917374T
Other languages
German (de)
English (en)
Inventor
John Andrew Todd
John Wilfred Hess
Charles Thomas Caskey
Roger David Cox
David Gerhold
Holly Hammond
Patricia Hey
Yoshihiko Kawaguchi
Tony Raymond Merriman
Michael Lee Metzker
Yusuke Nakagawa
Michael Sean Phillips
Rebecca Christina Joan Twells
Original Assignee
Wellcome Trust Ltd As Trustee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellcome Trust Ltd As Trustee, Merck & Co Inc filed Critical Wellcome Trust Ltd As Trustee
Application granted granted Critical
Publication of ATE359367T1 publication Critical patent/ATE359367T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
AT98917374T 1997-04-15 1998-04-15 Ldl-rezeptor ATE359367T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4355397P 1997-04-15 1997-04-15
US4874097P 1997-06-05 1997-06-05

Publications (1)

Publication Number Publication Date
ATE359367T1 true ATE359367T1 (de) 2007-05-15

Family

ID=26720554

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98917374T ATE359367T1 (de) 1997-04-15 1998-04-15 Ldl-rezeptor

Country Status (9)

Country Link
US (1) US6545137B1 (https=)
EP (1) EP0988379B1 (https=)
JP (1) JP4271735B2 (https=)
AT (1) ATE359367T1 (https=)
AU (1) AU733722B2 (https=)
CA (1) CA2286313C (https=)
DE (1) DE69837542T2 (https=)
ES (1) ES2285767T3 (https=)
WO (1) WO1998046743A1 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7244577B2 (en) * 1997-04-15 2007-07-17 Merck & Co., Inc. Method of screening for modulator of LRP5 activity
US6770461B1 (en) 1998-10-23 2004-08-03 Genome Therapeutics Corporation High bone mass gene of 11q13.3
US6780609B1 (en) 1998-10-23 2004-08-24 Genome Therapeutics Corporation High bone mass gene of 1.1q13.3
US6699466B1 (en) * 1999-08-05 2004-03-02 Research Corporation Technologies, Inc. IL-16 antagonist peptides and DNA encoding the peptides
FR2798138B1 (fr) * 1999-09-03 2004-05-21 Centre Nat Rech Scient Clonage, expression et caracterisation du gene spg4 responsable de la forme la plus frequente de paraplegie spastique autosomique dominante
IL151904A0 (en) * 2000-04-05 2003-04-10 Genome Therapeutics Corp THE HIGH BONE MASS GENE OF 11q13.3
DE60129433T2 (de) * 2000-05-26 2008-04-17 Oscient Pharmaceuticals Corp., Waltham Regulation des lipidniveaus über die gene zmax1 oder hbm
US7179462B2 (en) 2000-06-02 2007-02-20 University Of Connecticut Health Center α (2) macroglobulin receptor as a heat shock protein receptor and uses thereof
US7186515B1 (en) 2000-06-02 2007-03-06 University Of Connecticut Health Center Alpha(2) macroglobulin receptor as a heat shock protein receptor and uses thereof
EP1286693A4 (en) 2000-06-02 2005-07-13 Univ Connecticut Health Ct COMPLEXES OF ALPHA (2) MACROGLOBULIN AND ANTIGENIC MOLECULES FOR USE IN IMMUNOTHERAPY
EP1313753A4 (en) * 2000-08-18 2004-09-15 Proskelia REGULATORY GENE AND SYSTEM FOR USE IN THE DIAGNOSIS AND TREATMENT OF OSTEOPOROSIS
WO2002074906A2 (en) * 2001-03-16 2002-09-26 Eli Lilly And Company Lp mammalian proteins; related reagents
US20040221326A1 (en) * 2001-05-11 2004-11-04 Philip Babij Transgenic animal model of bone mass modulation
WO2002092000A2 (en) 2001-05-11 2002-11-21 Genome Therapeutics Corporation Hbm variants that modulate bone mass and lipid levels
US7514594B2 (en) * 2001-05-11 2009-04-07 Wyeth Transgenic animal model of bone mass modulation
US20040038860A1 (en) 2002-05-17 2004-02-26 Allen Kristina M. Reagents and methods for modulating dkk-mediated interactions
JP2005512508A (ja) * 2001-05-17 2005-05-12 ゲノム　セラピューティックス　コーポレーション Ｄｋｋ媒介性相互作用を変調する試薬および方法
CN1635896A (zh) 2001-08-20 2005-07-06 康涅狄格大学健康中心 包含用于治疗癌症及感染性疾病的热休克蛋白或α2－巨球蛋白的组合物制备方法
GB2381790A (en) * 2001-09-26 2003-05-14 Glaxo Group Ltd LDL-receptor polypeptides
JP2005220022A (ja) * 2002-03-08 2005-08-18 Anges Mg Inc Ｗｎｔの新規作用、及び、疾患治療への応用
US7169559B2 (en) * 2002-05-13 2007-01-30 Fonterra Corporate Research and Development Ltd. LDL receptor-related proteins 1 and 2 and treatment of bone or cartilage conditions
US20030219793A1 (en) * 2002-10-04 2003-11-27 Carulli John P. High bone mass gene of 11q13.3
WO2005049797A2 (en) 2003-11-17 2005-06-02 Merck & Co., Inc. Cynomolgus monkey dickkopf-4, nucleotides encoding same, and uses thereof
US7622553B2 (en) 2003-11-17 2009-11-24 Merck & Co., Inc. Rhesus monkey dickkopf-1, nucleotides encoding same, and uses thereof
WO2005048913A2 (en) * 2003-11-24 2005-06-02 Gunnar Westin Mutant lrp5/6 wnt-signaling receptors in cancer diagnosis, prognosis and treatment
EP2566892B1 (en) 2010-05-06 2017-12-20 Novartis AG Compositions and methods of use for therapeutic low density lipoprotein-related protein 6 (lrp6) antibodies
PH12012502193A1 (en) 2010-05-06 2021-08-09 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies
ES2666856T3 (es) 2011-11-04 2018-05-08 Novartis Ag Proteína 6 relacionada con lipoproteínas de baja densidad (LRP6) - constructos extensores de la vida media
EP3630816B1 (en) 2017-05-31 2024-03-20 Boehringer Ingelheim International GmbH Polypeptides antagonizing wnt signaling in tumor cells

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474796A (en) * 1991-09-04 1995-12-12 Protogene Laboratories, Inc. Method and apparatus for conducting an array of chemical reactions on a support surface
US5635177A (en) * 1992-01-22 1997-06-03 Genentech, Inc. Protein tyrosine kinase agonist antibodies
AU1173995A (en) * 1993-11-10 1995-05-29 Arch Development Corporation Ubiquitous nuclear receptor: compositions and methods
EP0758403B1 (en) * 1994-05-05 1998-06-24 Beckman Instruments, Inc. Oligonucleotide repeat arrays
ES2169804T3 (es) * 1995-06-23 2002-07-16 Us Gov Health & Human Serv Actividad despigmentante de la proteina señal aguti y peptidos de la misma.
IL151904A0 (en) 2000-04-05 2003-04-10 Genome Therapeutics Corp THE HIGH BONE MASS GENE OF 11q13.3

Also Published As

Publication number Publication date
AU733722B2 (en) 2001-05-24
DE69837542D1 (de) 2007-05-24
ES2285767T3 (es) 2007-11-16
EP0988379B1 (en) 2007-04-11
JP4271735B2 (ja) 2009-06-03
JP2002501376A (ja) 2002-01-15
AU7061498A (en) 1998-11-11
US6545137B1 (en) 2003-04-08
EP0988379A1 (en) 2000-03-29
CA2286313A1 (en) 1998-10-22
DE69837542T2 (de) 2008-01-31
CA2286313C (en) 2011-01-11
WO1998046743A1 (en) 1998-10-22

Similar Documents

Publication Publication Date Title
ATE359367T1 (de) Ldl-rezeptor
Huizing et al. Hermansky–Pudlak syndrome: mutation update
Lambrechts et al. Conventional and microfilled composite resins. Part II. Chip fractures.
Srinivas et al. Oral lichen planus-Review on etiopathogenesis
Kim et al. Decreased IL-12 production underlies the decreased ability of male lymph node cells to induce experimental autoimmune encephalomyelitis
EP0814158A3 (en) Human C3a receptor variant; uses in diagnostics and therapeutics
ATE380037T1 (de) Verfaheren zur durch rekombinante adeno- assoziierte virus-gerichtete gentherapie
Giurgea et al. TCF4 deletions in Pitt‐Hopkins syndrome
Tyas Clinical evaluation of a polyacid-modified resin composite (compomer).
Ke et al. The regulation of self-tolerance and the role of inflammasome molecules
Sohn et al. Clinical, biochemical, and genetic analysis of two korean patients with trichorhinophalangeal syndrome type I and growth hormone deficiency
Carter et al. Factors influencing the retention of cemented implant-supported crowns.
Hufnagl et al. Induction of mucosal tolerance with recombinant Hev b 1 and recombinant Hev b 3 for prevention of latex allergy in BALB/c mice
KR970704887A (ko) 혈청 파라옥소나제
EP1556493A4 (en) NEW COMPLETE GENETIC DNA OF THE JAPANESE CEPHALITIS VIRUS, INFECTIOUS JEV CDNA FROM AND THEIR USE
US8075894B2 (en) Use of soluble CD164 in inflammatory and/or autoimmune disorders
WO1997044454A3 (en) Human phospholipase inhibitor
MXPA02011588A (es) Regulacion de los niveles de lipidos a traves del gen zmax1 o hbm.
WO2000021983A3 (en) Tuberculosis vaccine and diagnostic reagents based on antigens from the mycobacterium tuberculosis cell
Tyas Three-year clinical evaluation of a polyacid-modified resin composite (Dyract).
EP1260228A3 (en) Human growth gene and short stature gene region. Therapeutic uses
Chassin et al. The human homolog of ribosomal protein S18
Liebers et al. Epitope mapping with peptides of Chi t I component III and immunomodulation of the Chi t immune response
EP0808900A3 (en) Polynucleotides and polypeptides associated with benign prostatic hypertrophy
JPH10304883A (ja) 新規化合物

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties